Latest Biobank Update

Our Lyme Disease Biobank has enrolled over 900 participants, supporting 55 research projects so far. We can support many more projects with serum, whole blood, urine and tissue samples available to researchers. The 2018 expansion of the Biobank to include tissue samples allows for a greater understanding of the ability of Lyme bacteria to invade tissues and organs. Learn more.



About the Lyme Disease Biobank

It is clear that much research needs to be conducted to make Lyme disease easy to diagnose and simple to cure. In order for researchers to discover and explore potential new diagnostics and treatments, they need blood, urine and tissue samples to use in their studies.

The Lyme Disease Biobank, a Bay Area Lyme research program, is working to obtain and characterize critical blood, urine and tissue samples for researchers. By collecting blood and urine from untreated patients with early-stage Lyme disease and patients with chronic disease as well as tissue samples from late-stage Lyme patients, this important program will help dramatically improve research efforts to accelerate medical breakthroughs in the understanding, diagnosis and treatment of Lyme disease and other tick-borne infections.

The Lyme Disease Biobank is a collection of more than 940 human biological samples that facilitates research of Lyme disease and other tick-borne infections.

Currently, there are more than 55 active research projects relying on Biobank samples. These projects are helping to pave the way for new diagnostics and therapeutics, as well as making strides to improve our understanding of Lyme and other tick-borne diseases and co-infections.


The Lyme Disease Biobank is working with collection sites throughout the country including Massachusetts General Hospital and Marshfield Clinic Research Institute, and others to collect blood and urine samples. Additionally, Lyme Disease Biobank collaborates with the National Disease Research Interchange (NDRI) for the collection of surgical and post-mortem tissue samples, and partners with, a project of, to pair samples with clinical information that can further enhance research.

History of Biobank

The Lyme Disease Biobank was conceived in early 2014 and launched with a Fund-A-Need campaign at our annual LymeAid benefit in May that same year. Just months later, collection began with a pilot study at a site on Long Island. Since then, we enrolled more than 900 participants from 8 collection sites on the East Coast, in upper Midwest, and in the Bay Area, California. The samples are annotated and characterized with detailed clinical information to support both cross-sectional and longitudinal studies. A generous donation from the Steven & Alexandra Cohen Foundation beginning in 2016 helped fortify the success of Lyme Disease Biobank.

In late 2018, Bay Area Lyme Foundation announced the addition of the Lyme Disease Tissue Collection Program to Lyme Disease Biobank, allowing for a greater understanding of the ability of Lyme bacteria to invade tissues and organs. Currently, the 900+ human biological samples collected by the Lyme Disease Biobank are enabling research in the field of Lyme disease and other tick-borne infections.

The Lyme Disease Biobank is a wholly-owned subsidiary of Bay Area Lyme Foundation.

To read the latest published studies on findings and news of these studies, click here.

Biobank Team


Principal Investigator

Liz Horn, PhD, MBI

Biobank Board

Linda Giampa, Executive Director, Bay Area Lyme Foundation

Bonnie Crater, Founder and Co-Chair of the Board of Directors, Bay Area Lyme Foundation 

Wendy Adams, Research Grant Director, Bay Area Lyme Foundation

A diverse group of more than 40 medical and scientific experts serve as volunteers to review applications for samples. Each application is reviewed by 2 peer reviewers with subject matter expertise relevant to the application.




We would like to recognize and thank the Steven & Alexandra Cohen Foundation, the LaureL STEM Fund, and the 2018 Fund-a-Need supporters who have contributed significantly to our Lyme Disease Biobank.